Microbiologic surrogate endpoints in clinical trials idsa fda idsa isap workshop april 15 2004 l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 22

Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 PowerPoint PPT Presentation


  • 130 Views
  • Uploaded on
  • Presentation posted in: General

Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004. Sheldon L. Kaplan, MD Baylor College of Medicine Texas Children’s Hospital Houston, TX. Sridhara et al http://www.fda.gov/www.fda.gov/cder/Offices/Biostatistics/presentations.htm.

Download Presentation

Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Microbiologic surrogate endpoints in clinical trials idsa fda idsa isap workshop april 15 2004 l.jpg

Microbiologic Surrogate Endpoints in Clinical Trials-IDSAFDA/IDSA/ISAP WorkshopApril 15, 2004

Sheldon L. Kaplan, MD

Baylor College of Medicine

Texas Children’s Hospital

Houston, TX


Slide2 l.jpg

Sridhara et al http://www.fda.gov/www.fda.gov/cder/Offices/Biostatistics/presentations.htm


Slide3 l.jpg

Sridhara et al http://www.fda.gov/www.fda.gov/cder/Offices/Biostatistics/presentations.htm


Infections for which microbiologic surrogate endpoints are useful for clinical trials l.jpg

Infections For Which Microbiologic Surrogate EndpointsAre Useful for Clinical Trials

  • Group A streptococcus pharyngitis

  • Uncomplicated lower urinary tract infection

  • Shigella gastroenteritis


Infections for which microbiologic surrogate endpoints are useful for clinical trials5 l.jpg

Infections For Which Microbiologic Surrogate EndpointsAre Useful for Clinical Trials

  • Group A Streptococcus Pharyngitis

    -symptoms will resolve regardless of therapy; time to resolution can be compared

    -suppurative and non-suppurative complications occur too infrequently to use as endpoints


Slide6 l.jpg

Infections For Which Microbiologic Surrogate EndpointsAre Not Useful or Unproven for Clinical Trials

  • Skin and skin structure infections

  • Pneumonia

  • Acute hematogenous osteomyelitis or septic arthritis

  • Intra-abdominal infections

  • Viral meningitis or encephalitis


Slide7 l.jpg

Infections For Which Microbiologic Surrogate EndpointsAre Not Useful or Unproven for Clinical Trials

  • Sites of infection are difficult to resample in order to document microbiologic eradication

  • Lack of eradication of the organism may not equal clinical failure-VAP and tracheal aspirates

  • Eradication of organism may not equal substantial clinical benefit-URI and pleconaril


Infections for which microbiologic surrogate endpoints may be useful for clinical trials l.jpg

Infections For Which Microbiologic Surrogate EndpointsMay be Useful for Clinical Trials

  • Bacterial meningitis

  • Acute otitis media and sinusitis

  • VP shunt infections

  • Coagulase-negative staphylococcus line-associated bacteremia

  • Pertussis


Antimicrobial drug development for acute bacterial meningitis joint fda idsa phrma workshop l.jpg

Antimicrobial Drug Development for Acute Bacterial MeningitisJoint FDA/IDSA/PhRMA Workshop

Imo Ibia, MD, MPH

Medical Officer

FDA/CDER/DSPIDP

November 20, 2002

Office of New Drugs IV

Center for Drug Evaluation and Research

www.fda.gov


Outcomes l.jpg

Outcomes

  • Are there data to show bacteriologic outcome is a good surrogate for clinical outcome?

  • Would bacterial endpoint alone miss the potential differential effect of drugs on inflammatory response?

  • How should clinical success/failure be defined and what should constitute the primary efficacy population?

    • ITT or evaluable?

  • How best can preclinical and early phase clinical trial data be used in meningitis trials to help address some of these issues?

Imo Ibia 2002 FDA/IDSA/PhRMA Workshop 2002


Evaluations l.jpg

Evaluations

  • Timing of repeat lumbar puncture

    • Is there data to establish the best time?

    • What factors could impact that time and how should they be factored in?

      • organism, baseline quantity, drug, host factors

  • How many organisms in repeat LP constitute delayed sterilization and what is its utility in trials?

    • Few and patient improving, optional (IDSA 1992)

  • Quantification of baseline CSF pathogens

    • How feasible and consistent across multinational sites?

  • Imo Ibia 2002 FDA/IDSA/PhRMA Workshop 2002


    Outcome of bacterial meningitis l.jpg

    Outcome of Bacterial meningitis

    • IDSA Guidelines 1992: Endpoints of

      -cure

      -survival with mild neurologic sequelae

      -survival with severe neurologic sequelae (somewhat

      dependent on the observer and some sequelae

      improve with time)

      -death

    • Mortality is low in US

    • Audiology testing is an objective and quantifiable measure

    • As with other sequelae, hearing loss may improve over time


    Ceftriaxone vs cefuroxime for bacterial meningitis in children l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    • Prospective, randomized multicenter study

    • Ceftriaxone (n=53) or cefuroxime (n=53)

    • Repeat CSF culture at 18-36 hours

    • No significant differences in clinical characteristics between the groups at enrollment

      Schaad et al N Engl J Med 1990;332:141-7


    Ceftriaxone vs cefuroxime for bacterial meningitis in children14 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    Schaad et al N Engl J Med 1990;332:141-7


    Ceftriaxone vs cefuroxime for bacterial meningitis in children15 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    • Hearing loss for H. influenzae type b

      Ceftriaxone-2/27 (7%); Cefuroxime-6/35 (17%)

    • 2 of 6 children who had hearing loss after cefuroxime therapy for Hib had delayed sterilization of the CSF i.e. 4 did not have delayed sterilization of CSF

    Schaad et al N Engl J Med 1990;332:141-7


    Ceftriaxone vs cefuroxime for bacterial meningitis in children16 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    • Hearing loss for S. pneumoniae

      Ceftriaxone-0/7; Cefuroxime-2/6

      None with hearing loss due to S. pneumoniae had delayed CSF sterilization

    Schaad et al N Engl J Med 1990;332:141-7


    Ceftriaxone vs cefuroxime for bacterial meningitis in children17 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    Sensitivity-90/99=91% Specificity-2/7=29%


    Ceftriaxone vs cefuroxime for bacterial meningitis in children18 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    • Four prospective studies conducted in Dallas-last 3 were dexamethasone trials. None of the studies were direct comparisons

    • Ceftriaxone-174; Cefuroxime-159

    • No significant differences between the groups at initiation of therapy

    Lebel et al J Pediatr 1989;114:1049-54


    Ceftriaxone vs cefuroxime for bacterial meningitis in children19 l.jpg

    Ceftriaxone vs Cefuroxime for Bacterial Meningitis in Children

    Lebel et al J Pediatr 1989;114:1049-54


    Meropenem vs cefotaxime for bacterial meningitis in children l.jpg

    Meropenem vs Cefotaxime for Bacterial Meningitis in Children


    Trovafloxacin vs ceftriaxone for bacterial meningitis in children l.jpg

    Trovafloxacin vs Ceftriaxone for Bacterial Meningitis in Children


    Conclusions l.jpg

    Conclusions

    • Not clear how well repeat CSF culture at 24-36 hours after initiation of treatment predicts hearing impairment or

      overall outcome (vast majority of patients with severe sequelae have sterile 2nd CSF)

      ● Not clear if findings for Hib meningitis are applicable to pneumococcal or meningococcal meningitis


  • Login